Subtype
Clear Cell Sarcoma of the Kidney
CI-CAN-00004977CCSKExplore in graph →
Pediatric10 evidence items
- NCIt
- C4264
- DOID
- 4880
- Other
- 1 more code
Loading cancer entity…
Subtype
CI-CAN-00004977CCSKExplore in graph →
Clinical trials
6 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (0)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00898365 | Study of Kidney Tumors in Younger Patients | completed | — | 8,000 | Children's Oncology GroupNETWORK | 7 | May 18, 2026 | clinicaltrials |
| NCT01061411 | Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 | 16 | Roswell Park Cancer InstituteOTHER | 2 | Aug 5, 2022 | clinicaltrials |
| NCT01154452 | Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma | completed | Phase 1 / Phase 2 | 78 | National Cancer Institute (NCI)NIH | 1 | Aug 15, 2018 | clinicaltrials |
| NCT01553539 | Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery | completed | Phase 2 | 20 | Wake Forest University Health SciencesOTHER | 1 | Jul 5, 2018 | clinicaltrials |
| NCT00335556 | Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors | completed | Phase 2 | 291 | Children's Oncology GroupNETWORK | 5 | Jul 21, 2017 | clinicaltrials |
| NCT01118078 | Biomarkers in Tissue Samples From Patients With High-Risk Wilms Tumor | completed | — | 185 | Children's Oncology GroupNETWORK | 1 | May 19, 2016 | clinicaltrials |
Data updated 22 days agoSource updated May 18, 2026source: clinicaltrials